Imagine replacing a painful needle biopsy or a long wait for an expensive MRI with a simple ultrasound scan. This technology uses smart computer programs to find and map prostate cancer tumors accurately. It lets the local doctor do the diagnosis right there in the office instead of sending the patient to a specialist.
Prostate cancer diagnosis currently relies on invasive biopsies with high sepsis risks or expensive MRIs with long waiting times and limited access. This creates a gap in patient care and increases national healthcare costs.
An ultrasound-based diagnostic method using advanced signal processing algorithms and a 3D mapping system validated against pathology ground truth data from 220 prostatectomies.
If you are an equipment provider dealing with high MRI costs and low accessibility — this project developed signal processing algorithms that make ultrasound equipment cost 96% less than MRI. This allows for broader market penetration in clinics.
If you are a clinic dealing with 35-day median waiting times for MRI scans — this project developed a tool that allows the urologist to perform the diagnosis directly. This removes the dependency on specialized radiologists and speeds up patient throughput.
If you are a health authority dealing with high national healthcare costs and sepsis risks of 8% from biopsies — this project developed a non-invasive imaging method. This reduces the risk of adverse health events and lowers overall spending.
The equipment for PCaVision costs 96% less than the MRI-based diagnosis methods currently used.
The project aims to roll out the solution to 16 EU clinics for long-term clinical demonstration to enable broad utilization.
Based on available project data, the project is coordinated by Angiogenesis Analytics BV, but specific licensing terms are not provided.
The project objective is to complete, validate, and certify the PCaVision solution for clinical use.
It addresses the gap caused by MRI waiting times, which currently have a median of 35 days.
The project is led by a single SME, Angiogenesis Analytics BV from the Netherlands. With a 100% industry ratio and a single partner, the project is streamlined for commercial transition rather than academic research, focusing heavily on clinical validation and certification.
Contact Angiogenesis Analytics BV in the Netherlands
Contact us to explore licensing opportunities for PCaVision signal processing algorithms.
